A drug application can be electronic and still behave like a truck full of paper. The files travel faster, but the work behind them remains stubbornly physical in spirit: find the source, copy the passage, rebuild the table, reconcile the version, ask who changed what, then repeat the exercise for the next regulator. Brandon Rice found his company-sized problem in that gap between a digital file and a genuinely digital system.
Rice is the CEO and co-founder of Weave Bio, a San Francisco software company that turns regulatory source material into connected dossiers. Its platform organizes data, drafts content, links claims back to their origins, manages review, and helps teams reuse approved material across a drug program. The pitch can sound like an application of generative AI to an old industry. His career suggests something more specific: this is the latest chapter in a long effort to make complicated scientific knowledge navigable.
Long before regulatory templates, there were Neanderthals. During graduate work in bioinformatics at the University of California, Santa Cruz, Rice studied variations inherited when Neanderthals and human populations interbred. He looked for mutations that had survived positive selection and tried to understand what they did in modern humans. The work was about relationships spread across an enormous body of information - how fragments connect, what persisted, and where a claim came from.
“My continual goal since grad school has been to leave a positive, enduring impact on the world.”Brandon Rice, reflecting on his career
Chapter oneThe genome assembler becomes a product person
At Santa Cruz, the lab did not remain only a lab. Rice and his adviser, Richard “Ed” Green, co-founded Dovetail Genomics around technology developed through that research environment. Rice joined in 2013 and helped with the young company’s business formation, intellectual property, foundational research, operations, and route to market. He served in a succession of roles including CEO, COO, and head of product development and strategy.
Dovetail’s work helped researchers assemble genomes at chromosome scale. Genome sequencing produces pieces; the useful artifact depends on knowing how those pieces belong together. Rice had moved from studying a difficult informational system to packaging a way for other scientists to handle one. His eventual shift into product management was not a departure from science. It was a decision about where he could be useful.
Find the scattered pieces. Preserve their relationships. Turn specialist knowledge into a product other people can operate.
The next decade took him through much of the life-sciences stack. At Freenome, he worked in scientific alliances and product management at a company applying machine learning and multi-omic data to cancer detection. At Synthego, he led software and functional-genomics products around CRISPR. At Resilience, he directed product management for drug-manufacturing platforms. Each stop changed the scientific setting. The practical question stayed familiar: how can emerging technology become a dependable workflow?
Chapter twoA difficult place to start
Rice announced in January 2023 that he was joining Weave as Head of Product. He later became chief product officer and co-founder, then moved into the CEO role in 2025 while continuing to oversee product. His co-founder Umut Eser brought machine-learning and computational-biology depth. Their target was regulatory development, the system of evidence and explanation that accompanies a therapeutic from early testing through market applications and later updates.
Weave began with Investigational New Drug applications, or INDs. Rice has recalled the objections: INDs were harder than clinical study reports, and the annual volume looked limited. The team read difficulty as architecture. If the platform could organize sources, generate traceable drafts, manage reviews, and publish a complex early submission, that workflow could become the base layer for the documents that followed.
The company publicly released AutoIND in May 2024 alongside a $10 million seed round co-led by Innovation Endeavors and Magnetic Ventures. In a later comparative study with Takeda, first drafting for large nonclinical written summaries fell from roughly 100 hours of traditional work to between 2.6 and 3.7 hours with the system. Independent reviewers reported no critical regulatory errors in the AI-generated drafts, while still identifying room to improve clarity and concision.
That final clause is the product. A fluent paragraph is easy to admire and difficult to trust when a filing has consequences. Weave keeps content connected to source material and treats human expertise as the decision layer. Rice describes AI as a way to return attention to the places where judgment adds value. The machine should do more of the finding, structuring, and first-pass writing. The regulatory scientist still decides whether the argument is accurate, complete, and appropriate.
Chapter threeThe proof phase
By 2025, generative AI had become easy to announce and harder to differentiate. Rice wrote after industry conferences that nearly every booth claimed an AI story. He called the next period the “proof” phase, defined by user happiness and organizational return. It was a useful standard for a company selling into cautious, highly regulated teams: demos would not be enough. The work needed numbers, partners, and filings.
Those signals arrived close together. Parexel, a global clinical research organization, became Weave’s design partner in September 2025. It brought regulatory expertise across clinical, nonclinical, pharmacology, and manufacturing disciplines into the platform’s development. Parexel reported completing IND work 50 percent faster than traditional authoring timelines. The relationship later expanded into NDA workflows, where the data, number of authors, and volume of content rise sharply.
In October, Weave announced a $20 million Series A led by USVP, with Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital participating. The round brought total disclosed funding to $36 million. The intended uses were concrete: finish coverage of the therapeutic regulatory lifecycle, expand beyond the United States, grow the commercial team, and build AI capabilities that could help with decisions across a portfolio.
“The science doesn’t change when you cross a border. The submission structure does.”Brandon Rice on global regulatory work
In 2026, that roadmap became visible. Weave added NDA support designed with Parexel, launched global-submission capabilities beginning with a European clinical-trial template, and continued developing its manager for questions from health authorities. Rice also convened a strategic advisory board with experience spanning major pharmaceutical companies, Stanford, and investment. The board’s job reflects the company’s broader method: put the people who understand the workflow near the people building the software.
Rice carries the product sensibility into the CEO job. He sets strategy, leads execution, and drives financing, but still oversees product because Weave treats product and company identity as intertwined. It is a revealing arrangement. Many founders move away from the object they are building as the organization grows. Rice has kept one hand on the workflow, the part where an abstract corporate promise meets a tired regulatory writer and either helps or does not.
He does not present that work with the solemnity the subject might invite. After filming an interview at the New York Stock Exchange, Rice wrote about expecting the commotion of Trading Places and finding a calm, digitized floor where nobody appeared concerned with orange-juice futures. The joke doubled as a product observation. A familiar institution had changed underneath its old public image. Regulatory work is in a similar moment: the dossier looks recognizable, even as the machinery capable of producing it is being rebuilt.
The wagerDocuments that remember
The larger idea is not faster typing. It is a different model for institutional memory. A regulatory dossier contains facts that will be repeated, reframed, updated, and examined across years. In a file-based process, every reuse invites another copy and every copy creates another version. In a connected system, a team can treat approved content and its evidence as durable components. The format can change for a jurisdiction without forcing the science to be rediscovered.
That is why Rice’s background matters. Bioinformatics trained him to care about provenance and structure. Dovetail taught him how to commercialize a method born in research. Freenome, Synthego, and Resilience put him inside distinct parts of the path from biological insight to manufactured therapy. Product management taught him that technical power has little value if the user cannot direct it or trust the result.
Rice has been candid that his goal of creating an enduring impact proved harder than he expected, especially inside startups with their chaos and dynamism. He kept the goal and changed the venue. That persistence feels more revealing than a tidy founder myth. Weave is not the first place he tried to make science more usable. It is the place where the fragments of his career currently assemble.
The company still has to prove that connected regulatory work can become normal across organizations, jurisdictions, and years of a program. Rice’s ambition is a document-light future in which knowledge, rather than the latest Word file, becomes the primary object. If it works, the visible outcome will be quicker drafting. The quieter outcome will matter more: fewer expert hours spent reconstructing what the organization already knew.